Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

149 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Disruption of the EGFR E884-R958 ion pair conserved in the human kinome differentially alters signaling and inhibitor sensitivity.
Tang Z, Jiang S, Du R, Petri ET, El-Telbany A, Chan PS, Kijima T, Dietrich S, Matsui K, Kobayashi M, Sasada S, Okamoto N, Suzuki H, Kawahara K, Iwasaki T, Nakagawa K, Kawase I, Christensen JG, Hirashima T, Halmos B, Salgia R, Boggon TJ, Kern JA, Ma PC. Tang Z, et al. Among authors: boggon tj. Oncogene. 2009 Jan 29;28(4):518-33. doi: 10.1038/onc.2008.411. Epub 2008 Nov 17. Oncogene. 2009. PMID: 19015641 Free PMC article.
EGFR mutation and resistance of non-small-cell lung cancer to gefitinib.
Kobayashi S, Boggon TJ, Dayaram T, Jänne PA, Kocher O, Meyerson M, Johnson BE, Eck MJ, Tenen DG, Halmos B. Kobayashi S, et al. Among authors: boggon tj. N Engl J Med. 2005 Feb 24;352(8):786-92. doi: 10.1056/NEJMoa044238. N Engl J Med. 2005. PMID: 15728811 Free article.
EGFR-mutated lung cancer: a paradigm of molecular oncology.
Zhang Z, Stiegler AL, Boggon TJ, Kobayashi S, Halmos B. Zhang Z, et al. Among authors: boggon tj. Oncotarget. 2010 Nov;1(7):497-514. doi: 10.18632/oncotarget.186. Oncotarget. 2010. PMID: 21165163 Free PMC article. Review.
Activation of the AXL kinase causes resistance to EGFR-targeted therapy in lung cancer.
Zhang Z, Lee JC, Lin L, Olivas V, Au V, LaFramboise T, Abdel-Rahman M, Wang X, Levine AD, Rho JK, Choi YJ, Choi CM, Kim SW, Jang SJ, Park YS, Kim WS, Lee DH, Lee JS, Miller VA, Arcila M, Ladanyi M, Moonsamy P, Sawyers C, Boggon TJ, Ma PC, Costa C, Taron M, Rosell R, Halmos B, Bivona TG. Zhang Z, et al. Among authors: boggon tj. Nat Genet. 2012 Jul 1;44(8):852-60. doi: 10.1038/ng.2330. Nat Genet. 2012. PMID: 22751098 Free PMC article.
EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy.
Paez JG, Jänne PA, Lee JC, Tracy S, Greulich H, Gabriel S, Herman P, Kaye FJ, Lindeman N, Boggon TJ, Naoki K, Sasaki H, Fujii Y, Eck MJ, Sellers WR, Johnson BE, Meyerson M. Paez JG, et al. Among authors: boggon tj. Science. 2004 Jun 4;304(5676):1497-500. doi: 10.1126/science.1099314. Epub 2004 Apr 29. Science. 2004. PMID: 15118125
149 results